Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono Research & Development Institute, Inc.
With
Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research \& Development Institute, Inc. / Merck KGaA, Darmstadt, Germany
* Merck Serono Co., Ltd (Japan)
Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment
Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists
You may not be if
Participants who are pregnant or breastfeeding
Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients
Participant has been enrolled in the comparator arm of avelumab parent study
Participant has been withdrawn from avelumab parent study for any reason
Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study
